Trastuzumab Deruxtecan in Patients With HER2+ Advanced Gastric or GEJ Cancer Who Progressed on or After a Trastuzumab-Containing Regimen
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study
Lancet Oncol 2023 Jun 14;[EPub Ahead of Print], E Van Cutsem, M di Bartolomeo, E Smyth, I Chau, H Park, S Siena, S Lonardi, ZA Wainberg, J Ajani, J Chao, Y Janjigian, A Qin, J Singh, F Barlaskar, Y Kawaguchi, G KuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.